Abstracts tagged "prevention"

Abstract Number: 1507 • 2016 ACR/ARHP Annual Meeting
Our Strategy of Preventing Tuberculosis (TB) in Patients with Rheumatic Diseases Under the Treatment with Biologic Dmards
Shinji Motojima¹, Tamao Nakashita², Akira Jibatake¹, Akira Yoshida¹ and Yoshiki Yamamoto¹, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan
Background/Purpose: According to the report by WHO, Japan is still in moderately-prevailing countries of TB. The annual incidence of TB in Japan is approximately 15/100,000,…
Abstract Number: 2042 • 2016 ACR/ARHP Annual Meeting
Improving the Overall Pneumococcal Vaccination Rate in Lupus Patients at the Rheumatology Clinic
Shivani Garg¹, Aliza Lipson² and Katina Tsagaris³, ¹Rheumatology, Emory University, Atlanta, GA, ²Rheumatology, EMORY UNIVERSITY, atlanta, GA, ³Rheumatology, EMORY UNIVERSITY, Atlanta, GA
Background/Purpose: The risk of developing invasive pneumococcal pneumonia is 13 times higher in Lupus patients in comparison with general population. CDC anticipates 7.6 Million-Dollar medical…
Abstract Number: 1030 • 2015 ACR/ARHP Annual Meeting
Unwanted Variations in Rheumatology Clinic Rooming: A Time Study Tool and Analysis
Brad Stroik¹, Christie M. Bartels², Diane Lauver³, Patrick McBride⁴, Jon Arnason², Sarah Loring³ and Edmond Ramly^5,6, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Wisconsin-Madison School of Nursing, Madison, WI, ⁴Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵Department of Medicine, University of Wisconsin-Madison, Madison, WI, ⁶Industrial and Systems Engineering, University of Wisconsin-Madison College of Engineering, Madison, WI
Background/Purpose: Facing fixed time for specialty visits, the time staff spends on rooming patients is a premium, but remains poorly understood. We conducted a time…
Abstract Number: 2126 • 2015 ACR/ARHP Annual Meeting
Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis
George D. Kitas¹, Peter Nightingale², Jane Armitage³, Naveed Sattar⁴, Jill Belch⁵, Deborah P.M. Symmons⁶ and TRACE RA Consortium, ¹Dudley Group NHS Foundation Trust, Dudley, and Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ²Wolfson Computer Laboratory, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Clinical Trial Service Unit and Epidemiology Unit, University of Oxford, Oxford, United Kingdom, ⁴University of Glasgow, BHF Glasgow Cardiovascular Research Centre, Glasgow, United Kingdom, ⁵Division of Cardiovascular and Diabetes Medicine, University of Dundee, Dundee, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for cardiovascular disease (CVD) compared to the general population, both due to classical and novel…
Abstract Number: 2502 • 2015 ACR/ARHP Annual Meeting
Implementation of New Pneumococcal Vaccination Recommendations in an Academic Rheumatology Clinic
Alison Bays¹, Renuka Nayak², David I. Daikh³, Jinoos Yazdany⁴ and Gabriela Schmajuk⁵, ¹Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, UCSF, San Francisco, CA, ³Rheumatology, UCSF/VA Medical Center, San Francisco, CA, ⁴Rheumatology, UCSF, SF, CA, ⁵San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA
Background/Purpose: Invasive pneumococcal disease is approximately four times more common among patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) compared to healthy counterparts.…
Abstract Number: 2306 • 2014 ACR/ARHP Annual Meeting
Quality of Care for Cardiovascular Prevention in RA: Compliance with Diabetes Screening Guidelines
Timothy J Schmidt^1,2, J Antonio Avina-Zubieta^2,3,4, Eric C. Sayre³, Michal Abrahamowicz⁵, John M. Esdaile^2,6,7 and Diane Lacaille^8,9,10, ¹Arthritis Research Centre of Canada, Richmind, BC, Canada, ²Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁵Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁶Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁷Rheumatology, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁸Arthritis Research Centre of Canada, Vancouver, BC, Canada, ⁹Medicine, University of British Columbia, Vancouver, BC, Canada, ¹⁰University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Background/Purpose: Comorbidities are increasingly recognized as significant contributors of decreased quality of life, and increased mortality in RA. RA is associated with an increased risk…
Abstract Number: 2307 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Disease Prevention in Rheumatologic Disease: Assessing Screening in a Primary Care Setting
Micaela Bayard¹ and Magdalena Cadet², ¹Rheumatology, New York Hospital of Queens/ Weill Cornell Medical Center, New York, NY, ²Rheumatology and Immunology, Duke University School of Medicine, Durham, NC
Background/Purpose: To determine the proportion of patients diagnosed with rheumatologic disease receiving preventive health care according to US Preventive Services Task Force recommendations with emphasis…
Abstract Number: 2308 • 2014 ACR/ARHP Annual Meeting
Quality of Care for Cardiovascular Disease Prevention in RA: Compliance Lipid Screening Guidelines
Timothy J Schmidt^1,2, J Antonio Avina-Zubieta^3,4,5, Eric C. Sayre⁴, Michal Abrahamowicz⁶, John M. Esdaile^3,7,8 and Diane Lacaille^9,10,11, ¹Arthritis Research Centre of Canada, Richmind, BC, Canada, ²Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Richmond, BC, Canada, ³Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Vancouver, BC, Canada, ⁴Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁵Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁶Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁷Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁸Rheumatology, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁹Medicine, University of British Columbia, Vancouver, BC, Canada, ¹⁰Arthritis Research Centre of Canada, Vancouver, BC, Canada, ¹¹University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Background/Purpose: Comorbidities are increasingly recognized as significant contributors of reduced quality of life and increased mortality in RA. Cardiovascular diseases are the leading cause of…
Abstract Number: 1410 • 2014 ACR/ARHP Annual Meeting
Low Rates of Cardiovascular Risk Factor Modification Among High-Risk Rheumatoid Arthritis Patients: Barrier to Cardiovascular Prevention Strategies?
Kimberly P. Liang¹, Rohit Aggarwal², Juan (June) Feng³, Jason Lyons³, Heather Eng³, Stephen R. Wisniewski³, Melissa Saul⁴, Douglas P. Landsittel⁵, Douglas W. Chew¹, Aryan Aiyer⁶ and Larry W. Moreland⁷, ¹Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁴Biomedical Informatics, University of Pittsburgh, School of Medicine, Pittsburgh, PA, ⁵Medicine, Biostatistics and Clinical and Translational Science, University of Pittsburgh, Center for Health Care Research Data Center, Pittsburgh, PA, ⁶Department of Medicine, Division of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Despite higher risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA), systematic cardiovascular (CV) prevention strategies are lacking. Recent guidelines for CV risk…
Abstract Number: 823 • 2014 ACR/ARHP Annual Meeting
Risk of Active Tuberculosis in Patients with Arthritis Receiving TNF-α Inhibitors: A Look Beyond the Baseline Tuberculosis Screening Protocol
Alina Soare¹, Carina Mihai², Ana Maria Gherghe², Rucsandra Dobrota², Raida Oneata², Simona Pintilie², Mihaela Milicescu², Ioan Ancuta², Andrei Martin², Mariana Sasu², Claudia Ciofu², Liviu Macovei², Victor Stoica² and Mihai Bojinca², ¹internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania, ²Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania
Background/Purpose Tuberculosis (TB) is a major concern in patients receiving TNF inhibitors (TNFi), especially in countries with a high TB burden. Careful TB screening is…
Abstract Number: 849 • 2013 ACR/ARHP Annual Meeting
Reasons For Failure To Obtain Influenza and Pneumococcal Vaccines Among Immunosuppressed Individuals With Systemic Lupus Erythematosus
Erica F. Lawson¹, Laura Trupin², Emily von Scheven³, Edward H. Yelin² and Jinoos Yazdany², ¹Pediatrics, University of California, San Francisco, San Francisco, CA, ²Medicine, UC San Francisco, San Francisco, CA, ³Pediatrics, UC San Francisco, San Francisco, CA
Background/Purpose: Infection is the third-leading cause of death in individuals with systemic lupus erythematosus (SLE) in developed countries. Nearly half of those deaths are attributed…
Abstract Number: 334 • 2013 ACR/ARHP Annual Meeting
The Joint Effect Of Carotid Ultrasound and Preventive Cardiology Referral On Cardiovascular Risk Factor Modification in Psoriatic Arthritis Patients
Michael Lucke¹, Soo Hyun Kim² and M. Elaine Husni³, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ³Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Cardiovascular disease risk is elevated in psoriatic arthritis (PsA) compared to the general population. Prior studies have demonstrated suboptimal evaluation and control of modifiable…
Abstract Number: 111 • 2013 ACR/ARHP Annual Meeting
Identifying Groups At Increased Risk Of Developing Rheumatoid Arthritis Using Family History and Genetic Risk Scores
Jeffrey A. Sparks¹, Chia-Yen Chen², Xia Jiang³, Johan Askling⁴, Linda T. Hiraki⁵, Lars Klareskog⁶, Lars Alfredsson³, Karen H. Costenbader⁷ and Elizabeth W. Karlson¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Epidemiology, Harvard School of Public Health, Boston, MA, ³Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ⁶Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁷Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The identification of high risk groups is crucial for RA prevention strategies. Individuals with family history (FH) of autoimmunity are at increased risk for…
Abstract Number: 2656 • 2013 ACR/ARHP Annual Meeting
Performance Of Prediction Models For Rheumatoid Arthritis Serologic Phenotypes Among Women Using Family History, Genetics and Environmental Factors
Jeffrey A. Sparks¹, Chia-Yen Chen², Xia Jiang³, Linda T. Hiraki⁴, Lars Klareskog⁵, Lars Alfredsson³, Karen H. Costenbader⁶ and Elizabeth W. Karlson¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Epidemiology, Harvard School of Public Health, Boston, MA, ³Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ⁵Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁶Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Family history (FH) of autoimmunity, genetics, and environmental factors have been associated with RA. The area under the receiver operating characteristic curve (AUC) can…
Abstract Number: 2460 • 2012 ACR/ARHP Annual Meeting
Dual Antiplatelet Therapy As Prophylaxis of Recurrent Arterial Thrombosis in Patients with　antiphospholipid Syndrome
Yuichiro Fujieda¹, Olga Amengual², Toshiyuki Watanabe¹, Michihito Kono², Yusaku Kanetsuka², Takashi Kurita², Toshio Odani¹, Kotaro Otomo¹, Toshiyuki Bohgaki², Tetsuya Horita², Shinsuke Yasuda² and Tatsuya Atsumi², ¹Medicine II, Hokkaido University, Sapporo, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Arterial thrombosis (AT) is a major clinicalmanifestation of the antiphospholipid syndrome (APS). A number of studies have evaluated the rate of recurrent thromboembolism, including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].